05/14/2026
After decades of advocacy, a landmark name change is here. 📋
Polycystic O***y Syndrome, known to millions as PCOS, has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS), following a rigorous, multistep global consensus published in The Lancet on May 12, 2026.
🔍 Why did the name need to change?
The term "polycystic" has long been recognized as clinically inaccurate. It implies the presence of pathological ovarian cysts, which are not a defining feature of the condition. The name also narrowed public and clinical understanding to the ovaries alone, obscuring the condition's true complexity. 📈 As a result, up to 70% of affected individuals remain undiagnosed.
PCOS involves a wide range of systems:
⚡ Endocrine: elevated androgens, insulin resistance, neuroendocrine disruption
🫀 Metabolic: type 2 diabetes risk, dyslipidemia, cardiovascular disease
🔬 Reproductive: ovulatory dysfunction, infertility, pregnancy complications
🧠 Psychological: depression, anxiety, eating disorders
🌿 Dermatological: acne, hirsutism, alopecia
💡 What does PMOS mean?
The new name was selected through global Delphi surveys, gathering 14,360 responses from patients and clinicians across all world regions, and expert consensus workshops. It was chosen to prioritize scientific accuracy, reduce stigma, and improve diagnostic clarity.
📌 What changes now?
The transition to PMOS will occur over 3 years, with updates planned across electronic health records, clinical guidelines (including the International PCOS Guidelines used in 195 countries), ICD disease classification, and medical education.
🌐 For the 170 million people living with this condition globally, this name change represents more than terminology. It's a step toward being seen, accurately diagnosed, and better understood.